Auryx Gold (AYX) Analysts See $-0.16 EPS, Proshare Advisors Boosted By $2.97 Million Its National Healthcare (NHC) Position

July 21, 2017 - By Nellie Frank

Analysts expect Auryx Gold Corp (TSE:AYX) to report $-0.16 EPS on August, 2 after the close.After having $-0.15 EPS previously, Auryx Gold Corp’s analysts see 6.67% EPS growth. It is down 0.00% since July 21, 2016 and is . It has underperformed by 16.70% the S&P500.

Proshare Advisors Llc increased National Healthcare Corp (NHC) stake by 90.71% reported in 2016Q4 SEC filing. Proshare Advisors Llc acquired 39,593 shares as National Healthcare Corp (NHC)’s stock declined 4.83%. The Proshare Advisors Llc holds 83,241 shares with $6.31 million value, up from 43,648 last quarter. National Healthcare Corp now has $1.05B valuation. The stock declined 0.36% or $0.25 reaching $68.67 on the news. About 15,031 shares traded. National HealthCare Corporation (NYSEMKT:NHC) has risen 12.74% since July 21, 2016 and is uptrending. It has underperformed by 3.96% the S&P500.

Auryx Gold Corp. is a mineral exploration firm engaged in the acquisition and exploration of undeveloped gold projects in Namibia. The company has market cap of $114.76 million. It is focused on advancing the Otjikoto Gold Project in which it holds a 92% indirect interest through its subsidiary, Auryx Gold (Namibia) (Pty) Ltd. It currently has negative earnings. It also holds a number of exploration licenses (EPLs), which comprise its Top Hat Project and its Accretive Terrane Project both in northeastern Namibia.

Since February 22, 2017, it had 0 buys, and 4 selling transactions for $695,472 activity. Shares for $80,387 were sold by POWELL JULIA W on Friday, February 24. 4,000 National HealthCare Corporation (NYSEMKT:NHC) shares with value of $291,100 were sold by SMITH JEFFREY RUSSELL.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: